Valuation: Atossa Therapeutics, Inc.

Market Cap 23.75M 21.31M 19.7M 17.84M 33.33M 2.26B 33.74M 236M 93.82M 1.18B 89.13M 87.25M 3.76B P/E 2026 *
-0.64x
P/E 2027 * -0.86x
Enterprise Value 23.75M 21.31M 19.7M 17.84M 33.33M 2.26B 33.74M 236M 93.82M 1.18B 89.13M 87.25M 3.76B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.3%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Atossa Therapeutics, Inc.

1 day-0.42%
1 week-6.69%
Current month+21.54%
1 month+24.74%
3 months+0.42%
6 months-56.51%
Current year-73.22%
1 week 2.36
Extreme 2.36
2.85
1 month 1.95
Extreme 1.95
3.12
Current year 1.7
Extreme 1.7
10.95
1 year 1.7
Extreme 1.7
14.85
3 years 1.7
Extreme 1.7
34.65
5 years 1.7
Extreme 1.7
43.62
10 years 1.7
Extreme 1.7
468
Manager TitleAgeSince
Chief Executive Officer 75 01/04/2009
Director of Finance/CFO 50 14/10/2025
Chief Tech/Sci/R&D Officer - 01/10/2025
Director TitleAgeSince
Chairman 75 01/04/2009
Director/Board Member 64 01/04/2009
Director/Board Member 79 01/07/2011
Date Insider Type Main position Quantity % Market Cap. Importance
12/05/26
Ensisheim Partners LLC
OtherCompany 0 0% -
12/05/26 Free

Director

10,000 0.1161%
12/05/26 Free

Director

10,000 0.1161%
Change 5-day change 1-year change 3-year change Capi.($)
-0.42%-6.69%-83.25%-76.38% 23.75M
+0.65%-3.56%+33.53%+60.50% 63.48B
+1.76%+2.10%+12.10%+81.21% 54.55B
-0.94%+0.77%+8.85%+100.19% 53.59B
+2.76%+4.18%+28.34%+55.07% 44.75B
+2.00%-2.90%+18.37%+119.04% 41.62B
+1.34%-3.98%+225.44%+914.08% 39.91B
+0.64%-3.85%+11.71%+45.57% 32.47B
+29.06%+48.65%+106.84%+92.73% 26.7B
+3.72%-7.45%+24.25%-2.99% 23.36B
Average +4.04%-1.01%+38.62%+138.90% 38.05B
Weighted average by Cap. +3.21%-0.29%+47.55%+161.46%

Financials

2026 *2027 *
Net sales - -
Net income -35.3M -31.67M -29.28M -26.52M -49.54M -3.36B -50.14M -350M -139M -1.76B -132M -130M -5.58B -38.03M -34.12M -31.54M -28.57M -53.37M -3.62B -54.01M -377M -150M -1.9B -143M -140M -6.02B
Net Debt - -
Projected Income Statement - Annual - Atossa Therapeutics, Inc.
Logo Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
Employees
16
Date Price Change Volume
29/10/26 $2.370 -0.42% 29,410
27/10/26 $2.380 -2.86% 24,834
26/10/26 $2.450 -5.77% 35,078
23/10/26 $2.600 -4.41% 77,024
22/10/26 $2.720 +7.51% 90,656
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Atossa Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.380USD
Average target price
19.00USD
Spread / Average Target
+698.32%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Atossa Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. ATOS Stock